Skip to main content
Premium Trial:

Request an Annual Quote

Cellectricon and Scientifica, Chip-Man Technologies, EDC Biosystems and Aurora Discovery, Evotec OAI, and Immunicon

Premium

Cellectricon Inks Scientifica as UK Distributor

Swedish biotech firm Cellectricon said last week that Scientifica will distribute Cellectricon’s DynaFlow platform for ion-channel drug discovery in the UK.

Scientifica will provide sales and technical support to Cellectricon in the UK market under the terms of the agreement.

Financial terms of the deal were not disclosed.

DynaFlow is a microfluidics- and cell-based assay system for high-throughput screening of ion-channel drug targets. It is based on highly parallel patch-clamping technology.


Finland's Chip-Man Raises €1.4M to Develop Cell-Analysis Platform

Chip-Man Technologies has secured €14 million ($18.4 million) in first-round financing, the firm said this week.

The cellular analysis technology company, based in Tampere, Finland, will use the funding, provided by Aura Capital and Finnish Industry Investment, to further develop its Cell-IQ cell analysis platform.

Chip-Man's Cell-IQ system monitors morphological and physiological changes in cell lines, primary cells, co-cultures, and monolayer tissue models in real time.

Chip-Man said that the market for automated cell analysis tools in pharmaceutical and medical research is estimated at around $500 million and is growing at 30 percent annually.


Aurora and EDC Biosystems Jointly Offer Microplates, Liquid Handling System

EDC Biosystems and Aurora Discovery will co-market their liquid-handling platform and microplates, the companies said this week.

Under the agreement, the companies will offer EDC’s EnRoute HTS 02 acoustic liquid-handling station and Aurora’s ChemLib 1,536-well or 3,456-well microplates for drug discovery research, including compound reformatting, hit picking, and compound library auditing.


Evotec to Report Year-End Financial Results March 22

Evotec OAI said last week that it would hold a conference call and webcast on Tuesday, March 22, at 8 a.m. EST to discuss its financial results for the year ended Dec. 31, 2004.

Interested parties may obtain more information on the conference call or access the webcast at http://www.evotecoai.com. A recording of the conference call will be available for 24 hours following the call, as will an on-demand version of the webcast, Evotec said.


Immunicon Gets FDA Nod for In Vitro Dx Use of Fluorescence Microscope

Immunicon said last week that its CellTracks Analyzer II, a semi-automated fluorescence microscope for enumerating fluorescently labeled cells, has been cleared by the US Food and Drug Administration as an in vitro diagnostic.

The microscope has specifically been cleared to enumerate fluorescently labeled cells that are “immuno-magnetically selected and aligned,” Immunicon said.

The system is used with kits that incorporate Immunicon reagents and the CellTrack AutoPrep system. The CellTracks Analyzer’s main application is detection and analysis of rare cells from patient samples.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.